Researchers say the data underscore the need for more aggressive surveillance of patients, even when AS is moderate AS.

These exploratory results from the FINEARTS-HF trial require confirmation in dedicated trials. REDEFINE-HF is underway.

The observed treatment rates, which “absolutely can go higher,” wouldn’t be acceptable for serious cancers, Stephen Greene ...

Current guidelines support culprit-only PCI in these cases, but the “hypothesis-generating” results suggest taking a closer ...

A decade on, there’s less revascularization with FFR-guided complete vs culprit only PCI, but COMPLETE-2 is on the way.

A sex gap seen in quality of life deserves further scrutiny, but the DISCHARGE trial data are still reassuring, says Maros ...

This month: shingles vaccine cuts CV events, brain injury impacts stroke risk, food insecurity’s health legacy, and more.

Tailoring the number of consults based on HF severity, which can be assessed pragmatically, could pay dividends, say ...

The results have implications not only for resource-limited parts of the world, but also for wealthier countries, one expert ...

As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

While the results bolster efficacy, questions remain about high costs and other issues with the ATTR-CM therapies.

STEMI criteria alone aren’t perfect for identifying occluded arteries, but still some question the need for a new paradigm.